Pà gina d'iniciNTLA • NASDAQ
add
Intellia Therapeutics Inc
8,99Â $
Fora d'hores:(0,44Â %)+0,039
9,03Â $
Tancat: 31 de des., 20:00:00 GMT-5 · USD · NASDAQ · ExempciĂł de responsabilitat
Tancament anterior
9,06Â $
Interval de preus d'avui
8,94Â $ - 9,14Â $
Interval anual
5,90Â $ - 28,24Â $
Capitalit. borsĂ ria
1041,31Â M USD
Volum mitjĂ
3,90Â M
RĂ tio preu-benefici
-
Rendibilitat per dividend
-
Borsa principal
NASDAQ
A les notĂcies
Finances
Balanç de resultats
Ingressos
Ingressos nets
| (USD) | set. del 2025info | VariaciĂł interanual |
|---|---|---|
Ingressos | 13,78Â M | 51,27Â % |
Despesa d'explotaciĂł | 46,31Â M | 3,59Â % |
Ingressos nets | -101,32Â M | 25,34Â % |
Marge de benefici net | -735,19 | 50,64Â % |
Benefici per acciĂł | -0,92 | 31,34Â % |
Ebitda | -109,06Â M | 23,28Â % |
Taxa impositiva efectiva | — | — |
Balanç
Actiu total
Passiu total
| (USD) | set. del 2025info | VariaciĂł interanual |
|---|---|---|
Efectiu i invers. a curt terme | 511,04Â M | -22,35Â % |
Actiu total | 925,28Â M | -21,14Â % |
Passiu total | 176,85Â M | -16,08Â % |
Capital total | 748,42 M | — |
Accions en circulació | 115,83 M | — |
Rà tio cotització-valor | 1,40 | — |
Rendiment | -30,56 % | — |
Rendibilitat d'inversió | -33,49 % | — |
Flux de caixa
VariaciĂł neta de l'efectiu
| (USD) | set. del 2025info | VariaciĂł interanual |
|---|---|---|
Ingressos nets | -101,32Â M | 25,34Â % |
Efectiu d'operacions | -76,90Â M | 9,36Â % |
Efectiu d'inversiĂł | -741,00Â k | 90,39Â % |
Efectiu de finançament | 114,86 M | 39,74 % |
VariaciĂł neta de l'efectiu | 37,22Â M | 459,45Â % |
Flux de caixa lliure | -81,93Â M | -128,85Â % |
InformaciĂł
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Conseller delegat, CO
Data de fundaciĂł
2014
Seu principal
Lloc web
Empleats
403
